TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

作者：Devendra Hiwase, Christopher Norman Hahn, Elizabeth Ngoc Hoa Tran, Rakchha Chhetri, Anmol Baranwal, Aref Al‐Kali, Kirsty Marie Sharplin, Dariusz Ladon, Rachel Hollins, Patricia Theresa Greipp, Monika Kutyna, Hassan B. Alkhateeb, Talha Badar, Paul Po-Shen Wang, David M. Ross, Deepak Singhal, Naranie Shanmuganathan, Peter Bardy, Ashanka Mahilal Beligaswatte, David T. O. Yeung, Mark Robert Litzow, Abhishek Avinash Mangaonkar, Pratyush Giri, Cindy S. Lee, Angie Yong, Noemi Horvath, Nimit Singhal, Raghu Gowda, William J. Hogan, Naseema Gangat, Mrinal M. Patnaik, Kebede H. Begna, Ing Soo Tiong, Andrew H. Wei, Sharad Kumar, Anna L Brown, Hamish S. Scott, DANIEL W. THOMAS, Chung Hoow Kok, Ayalew Tefferi, Mithun Vinod Shah · 发表于：Blood · 年份：2022 · DOI：10.1182/blood.2022018236 · 被引用次数：42 · 研究领域：Acute Myeloid Leukemia Research、Myeloproliferative Neoplasms: Diagnosis and Treatment、Chronic Myeloid Leukemia Treatments

Recent World Health Organization (WHO) 1 classifications (5 th edition), International Consensus Classification (ICC), 2 and the European LeukemiaNet (ELN) guidelines 3 included new categories for TP53-mutated (TP53 mut ) myeloid neoplasms (MNs) to acknowledge their uniformly poor outcomes and stimulate clinical research.However, there are critical differences in the details between these classifications, especially regarding single-hit TP53 mut status, and their significance relating to therapy-related myeloid neoplasm (t-MN), a rare but often fatal malignancy diagnosed following exposure to cytotoxic therapies, remains unclear.Here, we report an international cohort consisting of t-MN with full characterization of TP53 mut allele status and provide compelling evidence of poor outcome of TP53 mut t-MN irrespective of the allelic status of TP53.